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1. Introduction
Epilepsy in the general population occurs with an incidence of 44 per 100,000 person-years in
a population based study [1]. Symptomatic etiologies such as vascular injuries, infection, and
neoplasm are usually associated with a higher incidence of seizures and epilepsy. In the cancer
population, seizures arise mainly as a result of an infiltrative neoplastic process in the brain.
However, cancer treatment, metabolic causes, and paraneoplastic disease can also cause
seizures in this population despite the absence of a structural lesion. The etiology of epilepsy
in brain tumor patients includes primary malignancies and metastatic disease to the brain. A
multifaceted approach is required for treatment of seizures including surgery, radiation
treatment, chemotherapy, and antiepileptic drugs. A combination of treatments has the
potential of adverse effects and generally requires a multidisciplinary team.
This chapter will review the causes of epilepsy in cancer patients, incidence, treatment, the
role of electroencephalogram (EEG) and antiepileptic prophylaxis in this group of patients.
The factors which predispose seizures in these patients will also be reviewed, such as tumor
grade, histology and brain tumor morphology.
2. Incidence
The cumulative incidence of seizures in the general population is almost 10% by age 74. More
than 4% of the population has one unprovoked seizure by age 74 and 3% will develop epilepsy
[2]. Symptomatic etiologies such as brain tumors account for a higher percentage (30%-49%)
of all unprovoked seizures and epilepsy. Although brain tumors account for 4% of all epilep‐
sies, symptomatic seizures can occur in up to 85% of patients depending on tumor type and
location. In 30%-50% of patients with brain tumors a seizure is the presenting clinical sign.
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However, up to 30% will develop seizures later in the course of their disease [2]. In the cancer
population seizures can occur for numerous reasons including primary brain tumors, brain
metastasis, paraneoplastic syndromes, and other etiologies such as toxic/metabolic, infection,
or from a reaction to cancer treatment [3]. Drug interactions and adverse drug effects are
important considerations in this population as many treatments may have neurologic adverse
effects and seizures are one such problem.
Incidence rates of epilepsy based on etiology including brain tumors, traumatic brain injuries,
central nervous system (CNS) infections, cerebrovascular disease, and other causes have been
determined [4]. Symptomatic etiologies such as brain injuries and brain tumors account for a
higher percentage (30%-50%) of all unprovoked seizures and epilepsy.
The incidence of seizures in patients with systemic cancer is estimated to be 5%, but for patients
with an intracranial neoplasm, seizure incidence may be as high as 30% [5,6]. There are several
factors which affect the incidence of seizures in brain tumor patients and these include age,
location of the lesion, histology, and the grade of the tumor. With regard to age, there is a
higher incidence in young patients and those over age 65 which mirrors the incidence of
epilepsy in the general population [7,8]. The reason for this finding is likely the higher
incidence of low grade brain tumors in children versus adults and the subsequent longer
survival rate [9].
3. Etiology
Location, grade, histology and tumor morphology are important contributors to seizure
incidence.
Cortical location is an important determinant for the development of seizures as neural
generators are located in the cortex. Rarely do subcortical or infratentorial lesions cause
seizures. Location in the temporal, frontal, and parietal lobes are more likely to result in
seizures than occipital or subcortical lesions. Location near the rolandic fissure can also result
in seizures [8,10].
Grade of the tumor is an important determinant as low-grade lesions are more likely to be
associated with seizures. Chronicity of the lesion and subsequent secondary epileptogenesis
appear to play a role in the devolvement of seizures. Morphological characteristics of low-
grade lesions portend higher seizure incidence when compared to high-grade tumors. In one
study examining morphological characteristics, low grade gliomas tended to be larger in
patients presenting with seizures. This contrasted with patients with high grade gliomas where
patients who presented with seizures had smaller tumors. Location in the temporal lobe was
associated with higher seizure incidence for low-grade tumors [11].
Histology is an important contributor to the development of seizures and subsequent tumor
associated epilepsy as low-grade tumors are more often epileptogenic. Chronicity of the tumor
has been shown to be directly correlated with the incidence of seizures [12]. There are several
reasons for this: slow-growing tumors may isolate and deafferentate focal regions of normal
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tissue and prevent normal regulation. Low-grade brain tumors such as gangliogliomas and
dysembryoplastic neuroepithelial tumors can have an almost 100% incidence of seizures
whereas the incidence rate is 60%-85% in low-grade astrocytomas and oligodendrogliomas
(Fig. 1) [13].
4. Causes of seizures
4.1. Brain tumors
Primary brain tumors. As discussed, tumor histology and grade of tumor are important
contributors to the development of seizures in primary brain tumor patients.
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Figure 1. Seizure Frequency Based on Tumor Type
Neuronal tumors have a higher incidence of seizures. One possible reason is that the popula‐
tion of neurons could be epileptogenic within the tumor whereas in the glial tumors the seizure
focus is generally in the peritumoral brain tissue [8].
Glial neuronal tumors also have a high incidence of seizures which is more likely due to cortical
involvement of the tumor. Secondary epileptogenesis can occur in up to one-third of brain
tumor patients where the epileptogenic focus does not correspond to the tumor location. The
process by which this occurs can be described as an actively discharging epileptogenic region
that induces a similar paroxysmal activity in the region distant from the original site. This
phenomenon has been seen in animal models and it is believed that it occurs in humans as
well. Secondary epileptogenesis can be seen in low-grade brain tumors in the temporal lobe
which have associated hippocampal sclerosis [14].
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Several other factors can affect epileptogenesis including imbalance between excitatory and
inhibitory pathways. Higher levels of excitatory neurotransmitters such as glutamate can
result in excitability of cortical neurons and therefore seizures [15]. Alkaline pH levels in
peritumoral brain tissue can also lead to epileptogenesis by disrupting levels of intracellular
and extracellular Na.
Morphologic changes in the peritumoral brain tissue such as aberrant neuronal migration,
persistent neurons and white matter, and changes in synaptic vesicles can result in seizures in
brain tumor patients. Changes in receptor binding sites for excitatory and inhibitory neuro‐
transmitters (GABA, NMDA) can affect epileptogenicity [16]. One example of this phenom‐
enon is seen in gliomas as they have been shown to have higher concentrations of inotropic
glutamate receptors which can lead to neuronal hyperexcitability with resultant seizures and
possible cell death [17].
Metastatic  lesions  account  for  a  smaller  percentage  of  patients  with  intracranial  neo‐
plasms who go on to develop seizures and epilepsy. Systemic cancers which occur more
commonly,  such  as  lung  and  breast  cancer,  tend  to  have  a  higher  incidence  of  brain
metastasis  and subsequent seizures.  Some cancers have a higher predilection for central
nervous  system metastasis  such  as  melanoma and,  depending  on  location,  may have  a
higher seizure frequency [18].
4.2. Treatment-related causes of seizures
Chemotherapy. Various chemotherapeutic agents can be toxic to the central nervous system
either directly or through other mechanisms which result in epileptogenesis or lower seizure
threshold.
Agents such as cytarabine, methotrexate, high-dose cisplatin, bevacizumab, ifosfamide,
vincristine, and nitrosoureas can cause seizures by direct central nervous system toxicity when
given systemically or in the case of methotrexate when given intrathecally [19].
Radiation therapy. For patients undergoing whole brain radiation for brain metastasis,
leptomeningeal disease, and for primary brain tumors, seizures can occur as a direct result of
radiation. Complications can occur acutely such as during radiation treatment. They can occur
early within weeks to months after radiation or they can occur late, 1-2 years after receiving
radiation treatment from radiation necrosis [19, 20].
4.3. Toxic/metabolic
Medication toxicity or withdrawal can result in symptomatic seizures. This can occur with
numerous different agents including antimicrobials, antipsychotic medication, antidepressant
medication, and, of course, antiepileptic drug medication.
Conditions which can cause seizures even in patients without cancer can also contribute to
seizures in those with a brain tumor such as renal or liver failure. Electrolyte disturbance
including disturbances of sodium, calcium, magnesium and glucose can precipitate seizures.
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Glucose disturbances in particular can also result in focal neurologic disturbances such as
seizures or stroke-like syndromes [21].
4.4. Paraneoplastic syndromes
There are several paraneoplastic syndromes which have been characterized and which
seizures are one symptom. Paraneoplastic limbic encephalitis has been associated with
numerous antibodies including anti-Hu, anti-Ma2, CRMP5, and amphiphysin. Recently,
antibodies have been associated with encephalitis and seizures in patients who may or may
not have a neoplasm. One such antibody has been the NMDA receptor antibody which was
initially described in women with ovarian teratoma but has also been found in children without
cancer [22].
5. Treatment
Treatment will be discussed for patients with brain tumor epilepsy. In general, treatment for
patients with systemic cancer without intracranial lesions will consist of antiepileptic drugs
only. In patients with intracranial lesions, there is a multifaceted approach which includes
antiepileptic drugs, surgery, chemotherapy, and radiation therapy.
5.1. Antiepileptic drugs
Antiepileptic drugs are a mainstay of treatment for seizures of any etiology. In patients with
cancer this is also true, but a consideration of drug interactions and drug metabolism is
important as patients receiving chemotherapy, with or without corticosteroids, can have
untoward drug interactions in combination with antiepileptic drugs [23]. This is usually the
case for some of the first generation antiepileptic drugs which can be hepatic enzyme inducers,
specifically of the cytochrome P-450 pathway. Drug interactions can also occur with antiepi‐
leptic drugs that are enzyme inhibitors. A benefit of the second and third generation antiepi‐
leptic drugs is that many are not metabolized through the same hepatic pathways as
chemotherapy agents or corticosteroids. In addition, there is less protein binding with these
agents which makes them more suitable for treatment in patients receiving concurrent
chemotherapy (Table 1).
Enzyme-inducing antiepileptic drugs can decrease the effects of corticosteroids and in turn
corticosteroids can also alter the metabolism of antiepileptic drugs resulting in decreased
serum levels [24]. Enzyme-inducing antiepileptic drugs can also have an effect on the serum
drug levels of chemotherapeutic agents such as nitrosureas, paclitaxel, cyclophosphamide,
etoposide, doxorubicin, and methotrexate. Temozolomide, an alkylating agent commonly
used for treating high-grade gliomas, has minimal CYP metabolism. One study documented
no effect of temozolomide on levels of topiramate or oxcarbazepine [25].
Treatment of seizures with antiepileptic drug therapy in brain tumor patients has been
evaluated in several retrospective trials (Table 2). Use of older antiepileptic drugs with
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adjunctive treatment with agents such as levetiracetam, lamotrigine, or topiramate have been
reviewed and shown to be safe and efficacious in the brain tumor population. There are varying
degrees of success with reports of seizure reduction in many patients and a smaller percentage
achieving seizure freedom. Follow-up in these studies has been variable and difficult to
compare.
Side effects of antiepileptic drug treatment are an important consideration. In patients with
brain tumors who have undergone craniotomy, radiation treatment, and who may or may not
be receiving chemotherapy, additional toxicity from antiepileptic drugs can be additive.
Common side effects such as cognitive impairment, bone marrow suppression, liver dysfunc‐
tion, electrolyte abnormalities, and dermatologic reactions are important considerations in
patients receiving this antiepileptic drug therapy. Side effects are more frequent in patients
with brain tumors compared to the overall population with epilepsy as was noted in the 2000
AAN Practice Parameter [33].
A benefit to the newer antiepileptic drugs is that there are fewer interactions with chemo‐
therapy, they can be used in clinical trials aimed at treatment of brain tumors, and at times
there can be a better side effect profile. However, side effects from antiepileptic drugs can
be seen more often in patients with brain tumors. This is likely because patients with brain
tumors have fixed neurologic deficits which can be worsened in the setting of drug toxicity
of any kind.
Treatment with antiepileptic drugs in the cancer population should be similar to treatment for
anyone with localization related epilepsy. Monotherapy should be the goal with the lowest
possible dose to control seizures and to avoid adverse side effects. Drugs which control focal
seizures with secondary generalization are desired and agents such as lamotrigine, carbama‐
zepine, and oxcarbazepine are generally well-tolerated [34]. Other agents which can have an
Enzyme inducers (CYP 450) Non-enzyme inducers
Phenytoin Gabapentin
Carbamazepine Lamotrigine
Phenobarbital Valproic acid (enzyme inhibitor)
Primidone Felbamate (enzyme inhibitor)
Oxcarbazepine Levetiracetam
Pre-gadolinium
Tiagabine
Topiramate
Zonisamide
Lacosamide
Table 1. List of antiepileptic drugs comparing those metabolized through the CYP 450 pathway and those that are
not
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effect on this population such as topiramate or valproic acid can be used. However, cognitive
side effects with topiramate may limit its dosing and therefore its efficacy. Valproic acid would
appear to be a good agent; however, it can cause drug interactions and liver toxicity. In patients
already receiving chemotherapy, the potential for liver toxicity and thrombocytopenia can be
a problem with valproic acid [35]. Valproic acid does have possible antitumor effects due to
inhibition of histone deacetylase (HDAC) [36]. There is recent evidence that in patients with
glioblastoma undergoing standard treatment, radiation treatment with concurrent temozolo‐
mide, receiving valproic acid for the treatment of seizures may be a survival benefit [35].
However, prospective studies examining this issue have yet to be performed. Whether this
survival benefit was seen due to HDAC effects or hepatic enzyme inhibitory properties was
unclear. In contrast, a study examining 620 patients with newly diagnosed glioblastoma found
an overall survival benefit and progression-free survival in patients who received an enzyme
inducing agent versus those who did not [37]. The role of enzyme inducing AEDs on survival
has not been established in the brain tumor population but is something that should be
prospectively analyzed in new clinical trials.
Levetiracetam and gabapentin have ideal properties in that neither is liver metabolized and
there are few if any drug interactions. In several retrospective studies, levetiracetam has been
well-tolerated in brain tumor patients but can be associated with mood disturbances [29, 30,
38]. Cognitive side effects and fatigue are also seen with use of this agent which can be
compounded in patients who have received brain radiation.
Author N Type Grade Primary AED Add-on
AED
Seizure Free (%) Seizure reduction
(%)
Hildebrand et
al26
234 R HGG VPA, CBZ, GBP,
LMT, others
13 NA
Maschio et al.27 14 P HGG, LGG LEV, VPA, LTG,
others
LCS 43 78
Wick et al.28 107 R HGG, LGG PHT, VPA, CBZ 30
Wagner et al.27 26 P HG VPA LEV 20 65
Mashio et al.30 19 P HG LTG, VPA, TPM,
OXC
LEV 47 72
Newton et al31 41 R HG PHT, CBZ LEV 59 90
Mashio et al.25 47 P HG, LG, BM PHT, CBZ, PB TPM 56 76
Perry et al.32 14 P HG PHT, CBZ,
Clobazam
GBP 57 100
N- number of patients; R- retrospective; P- prospective; HGG- high grade glioma; LGG-low grade glioma; HG- High grade;
LG- low grade; BM-brain metastases; LEV-levetiracetam; VPA-valproic acid; LTG- lamotrigine; GBP-gabapentin; CBZ-
carbamazepine; OXC-oxcarbazepine; LCS-lacosamide; TPM-topiramate; PB-phenobarbital
Table 2. AED drug trials in brain tumor patients
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5.2. Surgery
There are generally two approaches to surgery for brain tumor patients. The first and most
important is gross total resection of either the primary brain tumor or a metastatic lesion. A
secondary consideration can be additional removal of a seizure focus (lesionectomy) for
patients who present with seizures as a symptom of their brain tumor. Circumstances which
can limit lesionectomy are the location of the seizure focus in an eloquent area of cortex. In the
brain tumor population, surgery is almost always geared towards gross total resection which
has shown on its own to improve outcomes from a seizure standpoint [39]. However, there
remains a significant population of patients who undergo brain tumor surgery and continue
to have seizures postoperatively. Patients with lesions near the motor cortex are more likely
not to be surgically "cured" as the lesion causing seizures is unlikely to be amenable to surgical
resection. Therefore, these patients remain with symptomatic partial epilepsy.
In tumor associated epilepsy, seizures generally arise from the peritumoral brain tissue and
not from the mass. Tumor tissue is generally electrically inert and does not give rise to seizures.
Electrocorticography (Ecog) performed intraoperatively may assist in identifying a seizure
focus and aid the neurosurgeon in removal of the lesion. A study reviewing 35 patients with
intractable temporal lobe epilepsy due to benign lesions (ganglioglioma, DNET, cavernoma)
found 3-year post-operative seizure rates to be improved in patients who underwent Ecog
with additional removal of spike-positive areas [40]. However, there is no universal standard
established.
For temporal lobe lesions, the additional resection of mesial structures may be beneficial in
some cases. A series with patients with low grade temporal lobe tumors (DNET, ganglioglio‐
ma) with associated hippocampal sclerosis suggest that lobectomy with hippocampectomy is
preferable to tumor resection alone [41]. Overall, prognostic factors which favor control of
epilepsy with surgery are a shorter duration of epilepsy prior to surgery, a single focus on
EEG, a single lesion on neuroimaging, and complete tumor resection [10,41,39].
5.3. Chemotherapy
Chemotherapy is one of the primary treatment modalities for all types of metastatic and
primary central nervous system tumors. The use of chemotherapy can result in seizure
reduction for patients with primary brain tumors. Recent studies retrospectively reviewing
the use of temozolomide or nitrosoureas in patients with low grade glioma have shown a
reduction in seizures with some patients achieving seizure freedom [42-44].
Additionally, in patients with subependymal giant cell astrocytomas with tuberous sclerosis
complex, the mTor inhibitor, everolimus, has been associated with reduction of subependymal
tumors and subsequent improvement in seizures. Whether this agent is antiepileptogenic in
itself or causes a reduction of tumor bulk which improves seizures remains to be seen [45].
5.4. Radiation therapy
Treatment for glioblastoma with surgery followed by radiation with concurrent temozolomide
has been established as a standard of care. There have been small studies which have shown
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that radiation treatment for malignant lesions has also resulted in improvement in seizures
independent of antiepileptic drug adjustment [46, 47]. The EORTC 22845 randomized trial of
long-term efficacy of early versus delayed radiation treatment for low grade brain tumors
revealed an improvement in seizure frequency at one year post treatment. Although later data
points were not collected, this study shows what has been evident in clinical practice which is
that radiation treatment for low-grade brain tumors can improve seizure frequency [48].
6. Antiepileptic drug prophylaxis
6.1. Postsurgical patients
The role of prophylactic anticonvulsant medications in the perioperative period has been
reviewed for numerous tumor types including primary brain tumors and brain metastasis.
Prophylaxis appears effective for preventing early postoperative seizures but does not appear
to affect the delayed development of epilepsy [49]. Current practice is to use prophylactic
anticonvulsants during the first week after surgery and then to discontinue after that time
period [50]. The data on these recommendations are derived from the older anticonvulsants,
phenytoin, phenobarbital, and valproic acid. The newer generation antiepileptic drugs have
not been studied as rigorously in this setting and therefore recommendations for their use is
limited. However, recent studies using levetiracetam in this setting have been promising in
that there are few if any drug interactions and minimal adverse effects related to the use of
this drug [51,52]. Certain tumor types may not benefit from the use of prophylactic anticon‐
vulsants in the perioperative period, such as meningioma, as seen in a recent meta analysis
[53]. Prospective studies are needed to determine the validity and efficacy of prophylactic
anticonvulsants in the perioperative period with newer generation antiepileptic drugs. In view
of the minimal drug interactions and favorable side effect profile of these drugs, they may have
a role in early seizure prophylaxis after craniotomy.
6.2. Brain tumor patients
Both the American Academy of Neurology and the Association for Neurologic Surgeons/
Congress of Neurologic Surgeons recommend against routine prophylaxis with antiepileptic
drugs for patients with primary brain tumors or brain metastasis without a history of seizures
[33,54]. Treatment is recommended only after patients with brain tumors experience a seizure.
7. Role of Electroencephalogram in brain tumor patients
Altered mental status is a common clinical manifestation in patients with brain tumors and
seizures are one cause of altered mental status. In patients with overt clinical seizures, the
diagnosis is usually not in question and therefore treatment can be started immediately for
this potentially life-threatening problem. However, in patients with subtle clinical signs of
seizures or nonconvulsive seizures, the diagnosis is often not clear without the use of an EEG.
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The workup in patients in whom seizures are suspected can be accomplished with routine
bedside EEG or long-term monitoring (LTM) with continuous video EEG recording. The use
of LTM has increased, especially in intensive care unit (ICU) settings. One study reported
seizures in 110 (19%) of 570 critically ill patients who had continuous video EEG, most of whom
were in an ICU setting. Of note, 101 of these patients had nonconvulsive seizures. Therefore,
in that setting, seizures would have been missed had EEG not been used [55]. Clinical suspicion
should be high in patients with structural brain lesions with altered mental status and an EEG
may be beneficial for evaluating these patients.
8. Conclusion
Epilepsy in cancer patients can be from numerous causes including the cancer itself, cancer
treatment, or toxic metabolic etiologies. Numerous factors contribute to the development of
epilepsy in these patients. Adverse effects due to cancer treatment and antiepileptic drugs
should be recognized early as patients with brain tumors and epilepsy are more likely to
experience adverse effects. Treatment will be multifaceted and include antiepileptic drugs,
surgery, chemotherapy, and radiation treatment. A multidisciplinary approach is usually
needed for treatment of these complicated patients.
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